Despite recent advances in treatment, cancer continues to be one of the most lethal human 8 maladies. One of the challenges of cancer treatment is the extreme diversity among seemingly 9 identical tumors: while some tumors may have good prognosis and are treatable, others are quite 10 aggressive, and may lack of effective therapies. Most of this variability comes from wide-spread 11 mutations and epigenetic alterations. Using a novel omic-integration method, we have exploited 12 this molecular information to re-classify tumors beyond the constraints of cell type. Eight novel 13 tumor groups (C1-8) emerged, characterized by unique cancer signatures. C3 had better prognosis, 14 genome stability, and immune infiltration. C2 and C5 had higher genome instability and poorer 15 clinical outcomes. Remaining clusters were characterized by worse outcomes, along with higher 16 genome instability. C1, C7, and C8 were upregulated for cellular and mitochondrial translation, 17 and relatively low proliferation. C6 and C4 were also downregulated for cellular and mitochondrial 18 translation, and had high proliferation rates. C4 was represented by copy losses on chromosome 19 6, and had the highest number of metastatic samples. C8 was characterized by copy losses on 20 chromosome 11, having also the lowest lymphocytic infiltration rate. C6 had the lowest natural 21 killer infiltration rate and was represented by copy gains of genes in chromosome 11. C7 was 22 represented by copy gains on chromosome 6, and had the highest upregulation in mitochondrial 23 translation. We believe that, since molecularly alike tumors could respond similarly to treatment, 24 our results could inform therapeutic action. 25 Significance 26 Cancer has been traditionally studied as a family of different diseases from different anatomical 27 sites. Nevertheless, regardless of the tissue of origin, cancer can be characterized by molecular 28 alterations on mechanisms controlling cell fate and progression. In this study, we integrate 33 29 cancer types and show the existence of eight clusters with unique genomic signatures and clinical 30 characteristics, beyond the site of origin of the tumor. The study and treatment of cancer, based on 31 predominant molecular features, rather than site of origin, can potentially aid in the discovery of 32 novel therapeutic alternatives.
Introduction 34
In spite of recent advances that have improved the treatment of cancer, it continues to reign as one of the 35 most lethal human diseases. More than 1,700,000 new cancer cases and more than 60,000 deaths are 36 estimated to occur in the year 2019, in the United States alone 1 . Cancer can be considered a highly 37 heterogeneous set of diseases: while some tumors may have a good prognosis and are treatable, others are 38 quite aggressive, lethal, or may not have a standard of care [2] [3] [4] . Cancer can also defy standard classification: 39 a well classified tumor may not respond to standard therapy, as expected, and may behave as a different 40 cancer type [5] [6] [7] . Fortunately, with the advances of sequencing technologies, data has become available for 41
research as never before. The Cancer Genome Atlas (TCGA), for instance, offers clinical and omic (e.g. 42 genomic, transcriptiomic, and epigenenomic data) information from more than 10,000 tumors across 33 43 different cancer types 8 . Much of this omic data has the potential to enable us to classify tumors and to 44 explain the striking variation observed in clinical phenotypes 9-12 . 45
Omic integration has been successfully applied in previous classification efforts [13] [14] [15] [16] . These classifications 46
have highlighted how molecular groups of tumors highly agree with human cell types. Alternatively, we 47
hypothesize the existence of internal subtypes hidden by cell type and tissue characteristics influencing cell 48
behavior. These subtypes could be distinguished by molecular alterations unlocking cancerous cell-49
transformation events. To test this hypothesis, we have developed a statistical framework that summarizes 50 omic patterns in main axes of variation describing the molecular variability among tumors. Key features 51
characterizing each axis (i.e. features contributing the most to inter-tumor variability) are retained, while 52 irrelevant ones are filtered. Retained features are then used to cluster tumors by molecular similarities and 53
find specific molecular features representing each group. 54
Here we show that, after removing all tissue-specific effects, the cancer signal immediately emerges. The 55 new molecular aggrupation, emphasizing on shared tumor biology, has the potential of providing new 56 insights of cancer phenotypes. We expect this novel classification to contribute to the treatment of tumors 57 without a current standard of care, by for example, borrowing therapies from molecularly similar cases. 58
Results 59
Signal coming from tissue and cell type strongly influence a naïve initial classification of tumors across 60 cancer types. We performed omic integration based on penalized matrix factorization, in order to remove 61 tissue effects, and seek out a re-classification of tumors based on subtler omic patterns. Our method can be 62 illustrated in four steps (Figure 1 , Materials and Methods).
Step 1 consists of applying sparse Singular Value 63
Decomposition (sSVD) to an extended omic matrix X, obtained from concatenating a series of scaled and 64 normalized omic blocks for the same subjects. Briefly, the major axes of variation across tumors (i.e. left 65 principal components, or scores) and the matching features 'activities' (i.e. the right principal components, 66
or loadings) of X are found. Sparsity is then imposed on the activity values, so features with minor influence 67 over the variability among tumors, are removed.
Step 2 consists of identifying what features (expression of 68 genes, methylation intensities, copy gains/losses) influence these axes the most (i.e. features not removed 69 by sSVD) and mapping them onto genes and functional classes (e.g. pathways, ontologies, targets of micro 70 RNA).
Step 3 involves the identification of local clusters of tumors, following Taskensen et al. (2016) .
Step 71 4 involves the characterization of clusters in terms of molecular (e.g. genes, pathways, complexes, etc.) and 72
clinical (e.g. survival probability, immune infiltration, etc.) information, distinguishing each cluster from 73 the rest. 74
75

Figure 1: Omic integration and features selection method.
Step 1) Singular value decomposition of a 76 concatenated list of omic blocks and identification of major axes of variation.
Step 2) Identification of omic 77 features (expression of genes, methylation intensities, copy gains/losses) influencing the axes and mapping 78 them onto genes and functional classes (e.g. pathways, ontologies, targets of micro RNA).
Step 3) Mapping 79 major axes of variation via tSNE and cluster definition by DBSCAN.
Step 4) Phenotypic characterization 80 of each cluster of subjects. 81
Using samples from 33 different cancer types provided by The Cancer Genome Atlas (TCGA), and 82
accompanying information from whole genome profiles of gene expression (GE), DNA methylation 83
(METH) and copy number variant alterations (CNV), we re-classified tumors based on molecular 84 similarities between the three omics. This was done by first removing the non-cancer systematic effects of 85 tissue via multiplication of X by a linear transformation (see Materials and Methods section). 86 87
Data description. 88
The data, including information of sample size and type of sample (i.e. from normal, metastatic, or primary 89 tissue), demographics (age, sex, and ethnicity) and survival information (overall survival status and times), 90
are summarized in Table 1. Omic data included information for gene expression (GE, as standardized log  91 of RNAseq data for 20,319 genes), methylation (METH, as standardized M-values summarized at the level 92 of 28,241 CpG islands), and copy number variants (CNV, as standardized log of copy/gain intensity 93 summarized at the level of 11,552 genes). 94 
103
The first 50 main axes of variations of the extended omics matrix (selected by clear bend in the scree plot 104
of Eigen-values -see Material and Methods). The projection of the 50 axes onto two dimensions is shown 105 in Fig. S1 . As expected, cell-of-origin effects dominate the clustering of tumors at a pan-cancer level, with 106 clusters enriched by previously reported pan-cancer clusters (e.g. collection of gastric cancer, gliomas, 107 kidney and squamous tumors), types, and subtypes (e.g. Luminal and Basal breast tumors), and single 108 cancer types (e.g. Thyroid carcinoma, Prostate adenocarcinoma, etc.). 109
Re-classification of pan-cancer tumors based on similarities between omics after removing tissue 110 specific signals. 111
Once tissue signal was identified, it was removed from the extended omic matrix. Next, sparsity constraints 112
were imposed on the omic features in order to zero-out the features with irrelevant contribution to axes of 113 variation and cluster formation. The selected features (i.e. with non-zero effects) across the three omics 114 corresponded with the 18 th , 25 th , 33 th , and 38 th axes (sorted from more to less variance explained) and 115 mapped onto a total of 1200 genes. The cluster identification and projection onto two dimensions revealed 116 eight classes ( Figure 2 ). As a consequence of removing the effects of tissue localization, all clusters were 117 formed by samples coming from multiple cancer types. Some clusters differed statistically from their cancer 118 types composition (Table 2) . However, all cancer types overlapped with more than one cluster ( Fig. 2;  119 Table 2, bottom). Furthermore, this overlap was not influenced by previously reported subtypes ( Fig. S2 ). 120 features. Tumor clusters were obtained by sequential application of tSNE and DBSCAN algorithm for 123 5,408 samples across 33 cancer types. The contours reflect cluster membership, and the points' colors and 124
shapes represent similar anatomical site and cancer type, respectively. The two-dimensional tSNE 125 projection was obtained from the four deep principal axes of the extended omic matrix projected outside 126 the tissue specific effects, after performing sSVD and removing the first two axes. After re-classifying 127 tumors, the few samples coming from Kidney chromophobe tumors (KICH) did not map in any of the eight 128 clusters obtained. 129
Clinical and demographical characterization of tumor clusters. 130
Clusters differed statistically in terms of patient age (with Cluster 3 and 8 containing samples from slightly 131 younger patients) and sex (with Clusters 2 and 7 having significantly more females than Cluster 8, due to 132 their slightly higher composition of gynecological cancers) ( Table 2) . None of the clusters were 133 significantly associated with ethnicity (Table 2) . 134 135 
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The most notorious distinctions between clusters were their differences in prognosis and severity traits (Fig.  142  S3) . Cluster 3 (the largest cluster in Fig. 2 ) was distinguished by better prognosis/less severity cancer than 143 the remaining clusters, followed by Clusters 2, 5, 6 and 7. Clusters 4 and 8 were in general the ones with 144 worst prognosis and more aggressive tumors (Table 2) . Cluster 3 was also the one with fewest metastatic 145 samples ( Fig. S4 ), higher survival rates, highest tumor-free fraction, lowest stage, lowest intra-tumor 146
heterogeneity (ITH, that estimates the fraction of subclonal and clonal genomes in each sample 18 ), and 147 lowest proliferation (Table 2 , Fig S3) . By comparison, Clusters 4 and 8 had significantly more metastatic 148 samples than Cluster 3. Cluster 8 had also higher ITH rates than Cluster 3. The highest ITH rates were 149 found in Cluster 5. 150
Cluster 3 had also the lowest rates of non-silent mutations, aneuploidies, and homologous recombination 151 dysfunction (HRD). The remaining clusters were very similar in terms of genome instability indicators, 152 except for Cluster 2. This cluster had significantly higher rates of HRD than Cluster 3, but significantly 153 lower rates than every other cluster (Table 2 ). In terms of immune infiltration, Cluster 3 was characterized 154 by the highest rates of tumor suppressive immune cells and tumor infiltrating lymphocytes (Table 2) . In 155 addition, Cluster 6 had the lowest infiltration of activated natural killer (ANK) cells. Cluster 8 had also the 156 lowest lymphocytic and highest Th2 CD4+ infiltrations, respectively (Table 2) . 157
Gene signatures characterizing tumor clusters. 158
The clusters were also characterized by distinct sets of omic features, significantly enriched for functions 159 involved in cell cycle (DNA replication, DNA synthesis, and targets of hsa-mir-615-b, a micro RNA 160
involved in cell proliferation) and mitochondrial translation (initiation, elongation, and termination) ( Table  161 2). To study the pairwise differences across clusters, these gene sets were projected onto scores for each 162 gene, as linear combinations between the features' values mapping onto the gene (i.e. its expression, 163 methylation, and copy number values) and their corresponding activities (i.e. the features effects arising 164 from the sparsity constraints) (see Materials and Methods section). In general, Cluster 3 was characterized 165
by intermediate values of these scores, while the remaining clusters were characterized by higher (i.e. gene 166 set with higher expression than Cluster 3) or lower (gene sets with lower expression than in Cluster 3) gene 167 set scores. Clusters 2, 4, and 6 had significantly higher scores for cell proliferation, and significantly lower 168
for mitochondrial translation. Clusters 1, 7 and 8, on the other hand, had significantly lower scores of 169 proliferation and higher for mitochondrial translation. NONOG, FOLSL1, TEAD4, and FOXM1) and some of their targets (Fig. S5 ). However, the expressions of 179
TFs and their targets were not significantly correlated within or between clusters ( Fig. S5 ), suggesting 180 mechanisms of control of the gene expression other than TFs regulation. 181
We then interrogated all pair-wise comparisons between the scores of each one of the 441 significant genes 182 using Tukey tests ( Supplementary Table S2 ). We identified a subgroup of 123 significant genes that 183 distinguished each cluster from the rest (for example, POLH had significantly higher scores in Cluster 4 184 than in every other cluster). The genes characterizing each individual cluster were then used to define 185 signatures. With this criterion, only Clusters 1, 4, 6, 7, and 8 were characterized by distinct signatures of 186 57, 4, 23, 24, and 15 genes each, respectively. Since the gene scores are combinations of omic features, we 187 looked at the gene expression in each signature and the potential role of copy numbers and methylation in 188 regulating it (Figures 3-4 SNRPB, SNX5, SOX12, STK35, TBC1D20, TRMT6, UBOX5, VPS16, ZCCHC3, ZNF133 and ZNF343) were 195 also downregulated. From the group of genes with significant copy-losses and basal expression values 196 (TGM6, SOX13, PROKR2, PRND, OXT, LRRN4 and FERMT1), LRRN4 and FERMT1 were also 197 significantly hyper-and hypo-methylated, respectively (Figure 3) . 198
Cluster 4's signature was composed by four genes mapping onto chromosome 6: TDRD6, POLH, PAQR8 199 and GUCA1A. All these genes exhibited significant copy losses in Cluster 4, and all of them except 200 GUCA1A, were also downregulated. Additionally, POLH was hypo-methylated, while PAQR8 was hyper-201 methylated (Figure 3 ). 202 203 by 23 genes mapping onto chromosome 11: ALDH3B1, ANKRD13D,  211  ANO1, AQP11, ARRB1, EMSY, CCND1, CTTN, KRTAP5-10, LRP5, LRRC32, TESMIN, MYO7A, NUMA1,  212 PAK1, PPFIA1, RBM4, RPS6KB2, RSF1, SHANK2, TMEM134, TPCN2 and USP35. Every one of these 213 genes exhibited significant copy gains, and all of them were also significantly upregulated, except for three 214 genes with basal expression in Cluster 6: MYO7A, LRRC32, and ALDH3B1. Genes USP35, SHANK2, 215
Figure 3: Gene signatures for Clusters 1 and 4 in terms of gene expression, copy number variation,
MYO7A, LRRC32, CTTN, CCND1, ARRB1, and ALDH3B1 were additionally hypo-methylated, while genes 216 RSF1 and PPFIA1 were hyper-methylated ( Figure 4) . 217
Cluster 7's signature was composed by 24 genes mapping onto chromosome 6. All of these genes (BTBD9, 218  RRP36, CCND3, CNPY3, CUL7, FRS3, GUCA1A, BICRAL, KLC4, KLHDC3, LRFN2, MEA1, MED20,  219  MRPL2, MRPS10, PEX6, PPP2R5D, RPL7L1, SRF, TAF8, TBCC, TOMM6, TRERF1 , and UBR2) 220 exhibited significant copy gains. All of them were significantly up-regulated, except by LRFN2, GUCA1A, 221
BTBD9, that had basal levels in Cluster 7. Genes TRERF1, LRFN2, and FRS3 were additionally hypo-222 methylated, while GUCA1A was hyper-methylated ( Figure 4) . first column of panels), copy number variants (CNV, second column of panels), and DNA methylation 228 (METH, third column of panels), and summarized by Bonferroni confidence intervals (adjusting for all the 229 441 significant genes in at least one cluster). Dots represent the average of features values across samples. 230
Cluster 8's signature was composed by 15 genes mapping onto chromosome 11. All of these genes 231 (ALDH3B1, ANO1, CCND1, CPT1A, CTTN, LRP5, MRPL21, NADSYN1, PPFIA1, RNF121, RSF1,  232 SHANK2, TPCN2, UNC93B1, and USP35) exhibited significant copy losses. All of them except ANO1 233
(with basal levels in cluster 7) were significantly downregulated. Additionally, Genes USP35 and 234
NADSYN1 were significantly hyper-methylated, while UNC93B1, RSF1, MRPL21 and ANO1 were hypo-235 methylated (Figure 4) . 236
Discussion 237
Most pan-cancer classifications rely on molecular alterations that clearly discriminate between tissue of 238 origin 13, 15, 16, 19, 20 . However, as soon as tissue effects were removed, we have found that the cancer signal 239 immediately emerged. Distinct cancer classes were formed, containing tumors from different cancer types. 240
These classes were also characterized by very specific functional groups of omic features. We also noticed 241 that the main source of synergy across omics arose from strong positive correlations between gene 242 expression and copy number events. The expression of regulatory elements within the group of selected 243 features (including transcription factors and the micro RNA hsa-mir-615b) was, on the other hand, not 244 associated with the expression of their predicted targets. These observations support the role of copy 245 numbers as a major force affecting tumor progression 21-23 . Contrarily, methylation had a minor impact in 246 the definition of clusters. This result could be due to the role of methylation in the determination and 247 differentiation of cell types [24] [25] [26] . As a consequence, methylation effects were perhaps removed together with 248 cell-type effects. Nevertheless, abnormal methylation patterns might still have had a role in the expression 249 of some genes characterizing tumor classes (e.g. expression of LRN4 and GUCA1A negatively correlated 250
with promoter CpG islands average methylation). 251
The tumor clusters C1, C4, C6, C7, and C8 had exclusive signatures (i.e. different of every other cluster). 252
Interestingly, the clusters without distinct individual signatures were the ones with more favorable 253 outcomes (C3, C2, and C5). One possible explanation for this is the frequent correspondence between more 254 dramatic molecular alterations and worse clinical outcomes 27,28 . To gain insights about possible biological 255
interactions within each signature, we used the accompanying bibliographic results provided by the 256 STRING database 29 (see Material and Methods section). The literature suggests a wide overlap between 257 signatures in terms of gene functions (cell growth, division, small RNA metabolism, protein synthesis, 258 maturation and transport, and mitochondrial dysfunction). In the case of signature C1 (most genes down-259 regulated), the literature suggested NOP56 (a core component of the small nucleolar ribonucleic protein) 260
as a central element in the signature; interacting with MKKS, NAA20 and PTPRA (genes with roles on 261 mitotic division); ESF1, SNRPB, SNRPB2, POLR3F and CRNKL1 (involved in small RNA processing), 262
PCNA and ITPA (involved correct DNA replication and repair), UBOX5, RRBP1, RBCK1 and NRSN2 263
(protein synthesis, maturation and antigen presentation), RBBPP9 (resistance to growth inhibition of TGF); 264
SIRPA and DSTN (cell adhesion) 30-33 . In the signature C1, NOP56 could be a candidate for future 265 therapeutic intervention. Tumor suppressors NRSN2 and RBCK1 could also be considered. 266
The three downregulated genes from signature C4 were involved in small RNA maturation (TDRD6, micro 267
RNA expression and maturation), cell proliferation (PAQR8, plasma membrane progesterone receptor), and 268
DNA repair (POLH, DNA polymerase involved in DNA repair). From these groups, PAQR8 and TDRD6 269 could represent potential targets of therapy. Although neither of them has been directly related to cancer, 270
other members of the PAQR family of progesterone receptors are known tumor suppressors, while TDRD6 271 has been reported as frequently down-regulated in breast cancer, suggesting its potential use as biomarker 34 . 272
In the case of signature C6 (most genes upregulated), the literature suggests CTTN as interacting with two 273 groups of genes within the signature, either by co-expression or co-localization in amplicons. One group 274
consisted of invasion and anti-apoptotic related genes (e.g. SHANK, PAK1, PPFIA1) and ion transport 275 (ANO1 and TPCN2) 35, 36 . The other group consisted of CCND1 (cell cycle check points), LRPS (protein 276 synthesis), RSF1 (chromatin remodeling), and USP35 (protein turnover; through amplicon-mediated 277 overexpression in breast and gynecological cancers) 37,38 . Patients with signature C6 could perhaps benefit 278 by ANO1 inhibitory therapy 36 . 279
Signature C7 was characterized by multiple genes co-expressing with KLHDC3 (involved in homologous 280 recombination): MEA1 (spermatogenesis), CNPY3 (protein folding, antigen presentation), PPP2R5D 281
(direct catalytic activity), RRP36 (small RNA synthesis), CCND3 (cyclin, cell cycle checks points), and 282 MED20 (transcription). KLHDC3 also belongs to the protein turnover and antigen presentation pathway, 283
together with CUL7 and UBR2. The literature also suggests another group of co-expressing genes within 284 signature C7, consisting of RPL7L (ribosome), MRPL2 and MRPS10 (mitochondrial ribosome). These 285 genes have also been found to physically interact in cell culture 39, 40 . Signature C8 genes remarkably 286 overlapped with signature C6 genes, but exhibited opposite regulation (i.e. up-instead of down-regulated). 287
Additionally, the literature suggests interaction between CCND1, NADSYN1 and MRPL20 in signature 288
C8 41, 42 . NADSYN1 has been proposed as target of inhibitory therapy in cancer 43 , while MRPL20 has been 289 suggested as biomarker for gastric cancers 44, 45 . From symmetry with signature C6, patients with signature 290
C8 might possibly benefit from ANO1 inhibitory therapy 36 . 291
The molecular classification of tumors generated clusters with clear differences in prognosis and severity, 292
with C3 exhibiting better outcomes than the remaining clusters. C3 also resembled a previously reported 293
"inflammatory" type, in terms of immune infiltration and cancer type composition (enriched for prostate 294 adenocarcinoma, thyroid, and pancreatic carcinomas and having elevated values of markers for CD4+ Th17 295
and Th1 cells and low genomic instability) 18 . Although the remaining clusters were clearly distinguished in 296 terms of altered molecular processes, they were highly similar in terms of clinical and demographic 297
characteristics. Further exploration of the link between clusters' signatures and cancer phenotypes could 298 aid in the development of novel biomarkers and therapies. For instance, signatures in clusters enriched for 299 metastatic samples (C4 and C8) that remain one of the most severe cancer phenotypes could aid in the 300 development of more efficient therapies 46, 47 . Similarly, signatures could also rapidly address differences in 301 tumor heterogeneity (e.g. C8 and C5 were notoriously more heterogeneous than the rest). Differences in 302
immune infiltration (C6 with the lowest activated natural killers' infiltration and C8 with the lowest 303 lymphocytic one) could also imply the potential use of signatures to aid in immunotherapeutic decisions. 304
Given the possibility of unveiling different biological channels altered in tumors of similar clinical and 305 molecular characteristics, we believe this novel pan-cancer classification could aid in the identification of 306 therapies for cancers without standard of care. 307
Material and Methods 311
Pan-cancer data. The TCGA offers a demographically diverse sample with comprehensive and modern 312 multi-omic data. We retrieved data from 5,408 from 33 cancer types made available by the Genome Data 313
Commons (GDC) repository 48 To the left of the plus sign is the Frobenius norm (a matrix analogous of Euclidean distance) of the 360 difference between and the product of and . To the right of the plus sign is a penalty on the elements 361 of W to impose sparsity. The purpose of this penalty is to zero-out those features with minor contributions 362
to the columns of Z. To remove the effect of tissues, or other covariates that can influence the selection of 363
features, we pre-multiplied X by I -Q(Q'Q) -1 Q', where I is a diagonal matrix of ones, and Q is an indicator 364 matrix to represent the membership to a given organ or tissue. 365
Step
2) Identification of omic features (expression of genes, methylation intensities, copy gains/losses) 366
influencing the axes. The linear decomposition achieved by SVD is an intuitive and straightforward way 367 of integrating omics. However, the variability across omics can be governed by just a few features (i.e. 368
highly sparse data) or by groups of interdependent features (i.e. very redundant data). To handle these 369 limitations, we chose , ( ) to be the Elastic Net penalty 55 , ( ‖ ‖ 1 + (1 − )‖ ‖ 2 2 ), where 370
balances the regularization between LASSO and ridge regression types of regularization, and is associated 371
with the degree of sparsity (i.e. how many features enter in the model? (where z1 is the first column of Z and w1 is the first row of W) with coordinate descent for given values of 374
and , following the algorithm of 57 , as implemented in 58 , but with the following thresholding operator: 375 sign(w1)| |w1| -|+ / (1 − ) (where |x|+ represents the positive part x). Consecutive layers are then 376 obtained by subtracting the previous ones from X and repeating the same procedure, as many times as the 377 number of desired axes of variation. The optimal value for was empirically determined, as suggested by 57 . 378
We start by 1) calculating W over a dense grid of values for (lower yields less sparsity), 2) calculating 379 the proportion of variance of X explained by ZW (PVX) for each , and 3) choosing the at which PVX 380 has its minimum second derivative. Since PVX decreases monotonically with , this point represents a 381 drastic drop on PVX, suggesting that the most relevant features accounting for the data variability are 382 already incorporated 57 . The value was fixed to 0.5 to have an equal contribution of LASSO and Ridge 383
penalties. Once a subset of features was selected, we mapped them onto genes using annotation data of 384 genomic position downloaded from the USCE web browser tool (GRCh38 59 ). The enrichment of functional 385 classes (ontologies, pathways, complexes, etc.) among these genes was tested using the Enrichr package 60 . 386
Step 3) Mapping major axes of variation via tSNE and cluster definition by DBSCAN. Additionally, SVD 387
can be coupled with non-linear embedding methods to deal with highly heterogeneous data. Here, we 388 applied t -Stochastic Neighbor Embedding (tSNE) on 14 . tSNE is a technique that efficiently takes on 389 local neighborhoods present in high dimension (eventually representing clusters of data), and conserves 390 them while projecting onto a lower dimensional display 61 . This makes tSNE a very powerful technique to 391 reveal clusters, even in very heterogeneous and convoluted data settings 62 . The algorithm has two 392 fundamental parameters: perplexity (which accounts for the effective number of local neighbors), and cost 393 (related to the difference between the neighborhood's distribution in the higher and lower dimensional 394 spaces). Since low cost is an indication of displays more likely to reveal clusters, we selected the maps 395 corresponding with the lowest costs among perplexities of 50 and 100, using 100 thousand iterations to 396 ensure convergence. We applied Density-Based Spatial Clustering of Applications with Noise 397 (DBSCAN 63 ) to identify clusters. DBSCAN is one of the most powerful clustering techniques to delimit 398 clusters of irregular shape, such as the ones tSNE produces 64 . Essentially, DBSCAN identifies groups of 399 densely packed points, without the need of specifying the number of clusters a priori 63 . Neighborhoods of 400 nearby points can then be tuned by evaluating different cluster partitions over a grid of possible 401 neighborhood sizes. We tuned this parameter by maximizing the Silhouette score, as in Taskensen et al. 402
2016. 403
